SCUBE3 regulation of early lung cancer angiogenesis and metastatic progression

Clinical and Experimental Metastasis

Volumn 30, Issue 6, 2013, Pages 741-752

  Chou, Cheng Hung ^a   Cheng, Yi Fang ^a   Siow, Tiing Yee ^a,b   Kumar, Amit ^a   Peck, Konan ^a   Chang, Chen ^a  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Angiogenesis; DCE MRI; EMT; NSCLC; SCUBE3

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 1; FIBRONECTIN; GELATINASE A; GELATINASE B; INTERLEUKIN 8; MATRIX METALLOPROTEINASE 14; PROTEIN LYSINE 6 OXIDASE; SIGNAL PEPTIDE; SIGNAL PEPTIDE CUB EGF LIKE DOMAIN CONTAINING PROTEIN 3; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HEY 1; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PARAMETERS; BLOOD VESSEL PERMEABILITY; CANCER CELL CULTURE; CANCER CONTROL; CANCER GROWTH; CANCER MORPHOLOGY; CANCER SIZE; CELL ASSAY; CIRCULATING TUMOR CELL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DENSITY; DOWN REGULATION; EARLY CANCER; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; GENE SILENCING; GENETIC REGULATION; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING;

CALCIUM-BINDING PROTEINS; CAPILLARY PERMEABILITY; CELL LINE, TUMOR; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84887126011     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-013-9575-8     Document Type: Article

References (51)

1. Wu YY, Peck K, Chang YL, Pan SH, Cheng YF, Lin JC, Yang RB, Hong TM, Yang PC (2011) SCUBE3 is an endogenous TGF-beta receptor ligand and regulates the epithelial-mesenchymal transition in lung cancer. Oncogene 30:3682-3693
2. Shih JY, Yang PC (2011) The EMT regulator slug and lung carcinogenesis. Carcinogenesis 32:1299-1304
3. Alves CC, Carneiro F, Hoefler H, Becker KF (2009) Role of the epithelial-mesenchymal transition regulator Slug in primary human cancers. Front Biosci 14:3035-3050
4. Becker KF, Rosivatz E, Blechschmidt K, Kremmer E, Sarbia M, Hofler H (2007) Analysis of the E-cadherin repressor Snail in primary human cancers. Cells Tissues Organs 185:204-212
5. Folkman J (1996) New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 32A:2534-2539
6. Buckley DL, Drew PJ, Mussurakis S, Monson JR, Horsman A (1997) Microvessel density of invasive breast cancer assessed by dynamic Gd-DTPA enhanced MRI. J Magn Reson Imaging 7:461-464
7. Knopp MV, Weiss E, Sinn HP, Mattern J, Junkermann H, Radeleff J, Magener A, Brix G, Delorme S, Zuna I et al (1999) Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 10:260-266
8. Tuncbilek N, Tokatli F, Altaner S, Sezer A, Ture M, Omurlu IK, Temizoz O (2011) Prognostic value DCE-MRI parameters in predicting factor disease free survival and overall survival for breast cancer patients. Eur J Radiol 81(5):863-867
9. Tuncbilek N, Karakas HM, Altaner S (2004) Dynamic MRI in indirect estimation of microvessel density, histologic grade, and prognosis in colorectal adenocarcinomas. Abdom Imaging 29:166-172
10. Guo J, Reddick WE, Glass JO, Ji Q, Billups CA, Wu J, Hoffer FA, Kaste SC, Jenkins JJ, Ortega Flores XC et al (2011) Dynamic contrast-enhanced magnetic resonance imaging as a prognostic factor in predicting event-free and overall survival in pediatric patients with osteosarcoma. Cancer 118(15):3376-3385
11. Tofts PS, Kermode AG (1991) Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 17:357-367
12. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ et al (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10:223-232
13. Sturn A, Quackenbush J, Trajanoski Z (2002) Genesis: cluster analysis of microarray data. Bioinformatics 18:207-208
14. Zijlstra A, Mellor R, Panzarella G, Aimes RT, Hooper JD, Marchenko ND, Quigley JP (2002) A quantitative analysis of rate-limiting steps in the metastatic cascade using human-specific real-time polymerase chain reaction. Cancer Res 62:7083-7092
15. Hong TM, Chen YL, Wu YY, Yuan A, Chao YC, Chung YC, Wu MH, Yang SC, Pan SH, Shih JY et al (2007) Targeting neuropilin 1 as an antitumor strategy in lung cancer. Clin Cancer Res 13:4759-4768
16. Yuan A, Lin CY, Chou CH, Shih CM, Chen CY, Cheng HW, Chen YF, Chen JJ, Chen JH, Yang PC et al (2011) Functional and structural characteristics of tumor angiogenesis in lung cancers overexpressing different VEGF isoforms assessed by DCE- and SSCE-MRI. PLoS ONE 6:e16062
17. Massague J (2008) TGFbeta in Cancer. Cell 134:215-230
18. Hynes RO (2002) A reevaluation of integrins as regulators of angiogenesis. Nat Med 8:918-921
19. Eliceiri BP, Cheresh DA (2001) Adhesion events in angiogenesis. Curr Opin Cell Biol 13:563-568
20. Stetler-Stevenson WG (1999) Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 103:1237-1241
21. Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML (2005) Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 169:681-691
22. Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2:795-803
23. Bussolino F, Albini A, Camussi G, Presta M, Viglietto G, Ziche M, Persico G (1996) Role of soluble mediators in angiogenesis. Eur J Cancer 32A:2401-2412
24. Shao W, Wang W, Xiong XG, Cao C, Yan TD, Chen G, Chen H, Yin W, Liu J, Gu Y et al (2011) Prognostic impact of MMP-2 and MMP-9 expression in pathologic stage IA non-small cell lung cancer. J Surg Oncol 104:841-846
25. Shin SY, Kim JH, Baker A, Lim Y, Lee YH (2010) Transcription factor Egr-1 is essential for maximal matrix metalloproteinase-9 transcription by tumor necrosis factor alpha. Mol Cancer Res 8:507-519
26. Hegele A, Heidenreich A, Kropf J, von Knobloch R, Varga Z, Hofmann R, Olbert P (2004) Plasma levels of cellular fibronectin in patients with localized and metastatic renal cell carcinoma. Tumour Biol 25:111-116
27. Han JY, Kim HS, Lee SH, Park WS, Lee JY, Yoo NJ (2003) Immunohistochemical expression of integrins and extracellular matrix proteins in non-small cell lung cancer: correlation with lymph node metastasis. Lung Cancer 41:65-70
28. Jakowlew SB, Mariano JM, You L, Mathias A (1997) Differential regulation of protease and extracellular matrix protein expression by transforming growth factor-beta 1 in non-small cell lung cancer cells and normal human bronchial epithelial cells. Biochim Biophys Acta 1353:157-170
29. Han S, Khuri FR, Roman J (2006) Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res 66:315-323
30. Kim S, Bell K, Mousa SA, Varner JA (2000) Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol 156:1345-1362
31. Yang Z, Zhang X, Gang H, Li X, Li Z, Wang T, Han J, Luo T, Wen F, Wu X (2007) Up-regulation of gastric cancer cell invasion by twist is accompanied by N-cadherin and fibronectin expression. Biochem Biophys Res Commun 358:925-930
32. Jia D, Yan M, Wang X, Hao X, Liang L, Liu L, Kong H, He X, Li J, Yao M (2010) Development of a highly metastatic model that reveals a crucial role of fibronectin in lung cancer cell migration and invasion. BMC Cancer 10:364
33. De Larco JE, Wuertz BR, Furcht LT (2004) The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res 10:4895-4900
34. Petreaca ML, Yao M, Liu Y, Defea K, Martins-Green M (2007) Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8/CXCL8) is required for IL-8/CXCL8-induced endothelial permeability. Mol Biol Cell 18:5014-5023
35. Huang S, Mills L, Mian B, Tellez C, McCarty M, Yang XD, Gudas JM, Bar-Eli M (2002) Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol 161:125-134
36. Shi Q, Abbruzzese JL, Huang S, Fidler IJ, Xiong Q, Xie K (1999) Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res 5:3711-3721
37. Inoue K, Slaton JW, Kim SJ, Perrotte P, Eve BY, Bar-Eli M, Radinsky R, Dinney CP (2000) Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res 60:2290-2299
38. Mian BM, Dinney CP, Bermejo CE, Sweeney P, Tellez C, Yang XD, Gudas JM, McConkey DJ, Bar-Eli M (2003) Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clin Cancer Res 9:3167-3175
39. Strieter RM, Belperio JA, Phillips RJ, Keane MP (2004) CXC chemokines in angiogenesis of cancer. Semin Cancer Biol 14:195-200
40. Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, Strieter RM (2000) CXC chemokines in angiogenesis. J Leukoc Biol 68:1-8
41. Six I, Kureishi Y, Luo Z, Walsh K (2002) Akt signaling mediates VEGF/VPF vascular permeability in vivo. FEBS Lett 532:67-69
42. Galaup A, Cazes A, Le Jan S, Philippe J, Connault E, Le Coz E, Mekid H, Mir LM, Opolon P, Corvol P et al (2006) Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proc Natl Acad Sci USA 103:18721-18726
43. Westhoff B, Colaluca IN, D'Ario G, Donzelli M, Tosoni D, Volorio S, Pelosi G, Spaggiari L, Mazzarol G, Viale G et al (2009) Alterations of the Notch pathway in lung cancer. Proc Natl Acad Sci USA 106:22293-22298
44. Sahlgren C, Gustafsson MV, Jin S, Poellinger L, Lendahl U (2008) Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci USA 105:6392-6397
45. Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT, Chi JT, Jeffrey SS, Giaccia AJ (2006) Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440:1222-1226
46. Gao Y, Xiao Q, Ma H, Li L, Liu J, Feng Y, Fang Z, Wu J, Han X, Zhang J et al (2010) LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. Proc Natl Acad Sci USA 107:18892-18897
47. Wilgus ML, Borczuk AC, Stoopler M, Ginsburg M, Gorenstein L, Sonett JR, Powell CA (2011) Lysyl oxidase: a lung adenocarcinoma biomarker of invasion and survival. Cancer 117:2186-2191
48. Shankar J, Messenberg A, Chan J, Underhill TM, Foster LJ, Nabi IR (2010) Pseudopodial actin dynamics control epithelial-mesenchymal transition in metastatic cancer cells. Cancer Res 70:3780-3790
49. Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE, Heldin CH et al (1997) Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 389:631-635
50. Hayashi H, Abdollah S, Qiu Y, Cai J, Xu YY, Grinnell BW, Richardson MA, Topper JN, Gimbrone MA Jr, Wrana JL et al (1997) The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. Cell 89:1165-1173
51. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH, Wrana JL (2000) Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 6:1365-1375